翰森制药与罗氏子公司订立许可协议，里程碑付款最高可达14.5亿美元

Core Viewpoint - Hansoh Pharmaceutical (03692.HK) has entered into a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The licensing agreement grants Roche the rights to develop and commercialize HS-20110, a CDH17-targeted antibody-drug conjugate (ADC) currently in Phase I clinical trials for colorectal cancer (CRC) and other solid tumors in China and the U.S. [1] - Hansoh will receive an upfront payment of $80 million and is entitled to up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] Group 2: Financial Implications - The agreement includes potential tiered royalties on future product sales, which could significantly enhance Hansoh's revenue stream depending on the product's market performance [1]